Cardiac Failure Review最新文献_第7页

Fatal Enterovirus-related Myocarditis in a Patient with Devic's Syndrome Treated with Rituximab. 利妥昔单抗治疗德维克综合征患者致死性肠病毒相关性心肌炎

Cardiac Failure Review Pub Date : 2021-05-12 eCollection Date: 2021-03-01 DOI: 10.15420/cfr.2020.33

Ava Diarra, Guillaume Gantois, Mouna Lazrek, Basile Verdier, Vincent Elsermans, Hélène Zephir, Benjamin Longère, Xristos Gkizas, Céline Goeminne, Gilles Lemesle, Francis Juthier, Johana Bene, David Launay, Romain Dubois, Sandrine Morell-Dubois, Fanny Vuotto, Anne-Laure Piton

{"title":"Fatal Enterovirus-related Myocarditis in a Patient with Devic's Syndrome Treated with Rituximab.","authors":"Ava Diarra, Guillaume Gantois, Mouna Lazrek, Basile Verdier, Vincent Elsermans, Hélène Zephir, Benjamin Longère, Xristos Gkizas, Céline Goeminne, Gilles Lemesle, Francis Juthier, Johana Bene, David Launay, Romain Dubois, Sandrine Morell-Dubois, Fanny Vuotto, Anne-Laure Piton","doi":"10.15420/cfr.2020.33","DOIUrl":"https://doi.org/10.15420/cfr.2020.33","url":null,"abstract":"Enteroviruses are a frequent source of infection and among the most common central nervous system viral pathogens. Enteroviruses - in particular, the Coxsackie B viruses - are a known cause of myocarditis. Rituximab is a genetically engineered chimeric anti-CD20 monoclonal antibody. Many reports in the literature suggest a higher risk of infection following repeated rituximab therapy, including viral infection. However, observations of enterovirus-related myocarditis in the context of rituximab treatment are scarce. The authors describe the case of a patient with neuromyelitis optica spectrum disorder who developed severe and fatal enterovirus-related myocarditis after rituximab therapy with a difficult differential diagnosis of autoimmune or giant-cell myocarditis. This case highlights the importance of complete diagnostic workup in difficult cases of myocarditis, including endomyocardial biopsies.","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"7 ","pages":"e09"},"PeriodicalIF":0.0,"publicationDate":"2021-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/8a/7e/cfr-07-e09.PMC8135016.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39019202","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Hyperkalaemia in Heart Failure. 心力衰竭的高钾血症。

Cardiac Failure Review Pub Date : 2021-05-12 eCollection Date: 2021-03-01 DOI: 10.15420/cfr.2020.29

Umar Ismail, Kiran Sidhu, Shelley Zieroth

引用次数: 3

Digital Health: Implications for Heart Failure Management. 数字健康：对心衰管理的影响。

IF 4.2

Cardiac Failure Review Pub Date : 2021-05-11 eCollection Date: 2021-03-01 DOI: 10.15420/cfr.2020.28

Arvind Singhal, Martin R Cowie

{"title":"Digital Health: Implications for Heart Failure Management.","authors":"Arvind Singhal, Martin R Cowie","doi":"10.15420/cfr.2020.28","DOIUrl":"10.15420/cfr.2020.28","url":null,"abstract":"Digital health encompasses the use of information and communications technology and the use of advanced computing sciences in healthcare. This review covers the application of digital health in heart failure patients, focusing on teleconsultation, remote monitoring and apps and wearables, looking at how these technologies can be used to support care and improve outcomes. Interest in and use of these technologies, particularly teleconsultation, have been accelerated by the coronavirus disease 2019 pandemic. Remote monitoring of heart failure patients, to identify those patients at high risk of hospitalisation and to support clinical stability, has been studied with mixed results. Remote monitoring of pulmonary artery pressure has a consistent effect on reducing hospitalisation rates for patients with moderately severe symptoms and multiparameter monitoring shows promise for the future. Wearable devices and apps are increasingly used by patients for health and lifestyle support. Some wearable technologies have shown promise in AF detection, and others may be useful in supporting self-care and guiding prognosis, but more evidence is required to guide their optimal use. Support for patients and clinicians wishing to use these technologies is important, along with consideration of data validity and privacy and appropriate recording of decision-making.","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"7 ","pages":"e08"},"PeriodicalIF":4.2,"publicationDate":"2021-05-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/56/84/cfr-07-e08.PMC8135017.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39019201","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

CardioMEMS Implantation Using Gadolinium-based Contrast Agent: A Case Report. 基于钆造影剂的心脏ems植入:1例报告。

Cardiac Failure Review Pub Date : 2021-04-12 eCollection Date: 2021-03-01 DOI: 10.15420/cfr.2021.03

Aniket S Rali, Lynne W Stevenson, Sandip K Zalawadiya

引用次数: 0

Rationale for and Practical Use of Sacubitril/Valsartan in the Patient's Journey with Heart Failure and Reduced Ejection Fraction. 舒比利/缬沙坦在心力衰竭和射血分数降低患者治疗过程中的基本原理和实际应用

Cardiac Failure Review Pub Date : 2021-04-05 eCollection Date: 2021-03-01 DOI: 10.15420/cfr.2020.25

Mauro Gori, James L Januzzi, Emilia D'Elia, Ferdinando L Lorini, Michele Senni

{"title":"Rationale for and Practical Use of Sacubitril/Valsartan in the Patient's Journey with Heart Failure and Reduced Ejection Fraction.","authors":"Mauro Gori, James L Januzzi, Emilia D'Elia, Ferdinando L Lorini, Michele Senni","doi":"10.15420/cfr.2020.25","DOIUrl":"https://doi.org/10.15420/cfr.2020.25","url":null,"abstract":"Sacubitril with valsartan (sacubitril/valsartan) is a relatively novel compound that has become a milestone in the treatment of patients with chronic heart failure (HF) with reduced ejection fraction (HFrEF) in the last decade. Contemporary data suggest that sacubitril/valsartan is associated with improved outcomes compared with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, and has a greater beneficial effect on myocardial reverse remodelling. Additionally, two recent trials have shown that sacubitril/valsartan is well-tolerated even in the acute HF setting, thus enabling a continuum of use in the patient's journey with HFrEF. This article summarises available data on the effectiveness and tolerability of sacubitril/valsartan in patients with HFrEF, and provides the clinician with practical insights to facilitate the use of this drug in every setting, with an emphasis on acute HF, hypotension, electrolyte imbalance and renal insufficiency.","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"7 ","pages":"e06"},"PeriodicalIF":0.0,"publicationDate":"2021-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/40/12/cfr-07-e06.PMC8054374.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38900264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Representation of Women Physicians in Heart Failure Clinical Practice. 女性医生在心力衰竭临床实践中的代表性。

Cardiac Failure Review Pub Date : 2021-03-31 eCollection Date: 2021-03-01 DOI: 10.15420/cfr.2020.31

Ersilia M DeFilippis, Yasbanoo Moayedi, Nosheen Reza

引用次数: 4

Cardiovascular Outcomes in Trials of New Antidiabetic Drug Classes. 新型抗糖尿病药物试验的心血管结局。

Cardiac Failure Review Pub Date : 2021-03-05 eCollection Date: 2021-03-01 DOI: 10.15420/cfr.2020.19

Chris Wai Hang Lo, Yue Fei, Bernard Man Yung Cheung

引用次数: 10

Viscoelastic Haemostatic Assays in Cardiovascular Critical Care. 心血管危重症的粘弹性止血试验。

Cardiac Failure Review Pub Date : 2021-02-19 eCollection Date: 2020-03-01 DOI: 10.15420/cfr.2020.22

Aniket S Rali, Ahmed M Salem, Melat Gebre, Taylor M Garies, Siva Taduru, Arthur W Bracey

{"title":"Viscoelastic Haemostatic Assays in Cardiovascular Critical Care.","authors":"Aniket S Rali, Ahmed M Salem, Melat Gebre, Taylor M Garies, Siva Taduru, Arthur W Bracey","doi":"10.15420/cfr.2020.22","DOIUrl":"https://doi.org/10.15420/cfr.2020.22","url":null,"abstract":"The initiation and management of anticoagulation is a fundamental practice for a wide variety of indications in cardiovascular critical care, including the management of patients with acute MI, stroke prevention in patients with AF or mechanical valves, as well as the prevention of device thrombosis and thromboembolic events with the use of mechanical circulatory support and ventricular assist devices. The frequent use of antiplatelet and anticoagulation therapy, in addition to the presence of concomitant conditions that may lead to a propensity to bleed, such as renal and liver dysfunction, present unique challenges. The use of viscoelastic haemostatic assays provides an additional tool allowing clinicians to strike a delicate balance of attaining adequate anticoagulation while minimising the risk of bleeding complications. In this review, the authors discuss the role that viscoelastic haemostatic assay plays in cardiac populations (including cardiac surgery, heart transplantation, extracorporeal membrane oxygenation, acute coronary syndrome and left ventricular assist devices), and identify areas in need of further study.","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"7 ","pages":"e01"},"PeriodicalIF":0.0,"publicationDate":"2021-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/62/ec/cfr-07-e01.PMC7919676.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25467261","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Clinical Characteristics of De Novo Heart Failure and Acute Decompensated Chronic Heart Failure: Are They Distinctive Phenotypes That Contribute to Different Outcomes? 新发心力衰竭和急性失代偿慢性心力衰竭的临床特征：它们是导致不同结果的独特表型吗？

IF 4.2

Cardiac Failure Review Pub Date : 2021-02-19 eCollection Date: 2020-03-01 DOI: 10.15420/cfr.2020.20

Wilson Matthew Raffaello, Joshua Henrina, Ian Huang, Michael Anthonius Lim, Leonardo Paskah Suciadi, Bambang Budi Siswanto, Raymond Pranata

引用次数: 0

Pulmonary Embolism and Heart Failure: A Reappraisal. 肺栓塞和心力衰竭:重新评估。

Cardiac Failure Review Pub Date : 2021-02-18 eCollection Date: 2020-03-01 DOI: 10.15420/cfr.2020.26

Mattia Arrigo, Lars Christian Huber

引用次数: 12